| abstract |
Disclosed herein are compounds that inhibit the kinase activity of dual leucine zipper (DLK) kinase (MAPK12), pharmaceutical compositions, and DLK-mediated diseases such as central nervous system neurons and peripheral nervous system. Neurological disorders resulting from traumatic injury to neurons (eg, stroke, traumatic brain injury, spinal cord injury) or diseases resulting from chronic neurodegenerative conditions (eg, Alzheimer's disease, frontotemporal dementia, Parkinson's disease, Huntington's disease) Diseases resulting from neuropathy due to nerve injury, chemotherapy-induced peripheral sclerosis, spinocerebellar ataxia, progressive supranuclear palsy, Lewy body disease, Kennedy disease, and other related conditions) Neuropathy, diabetic neuropathy, and related conditions) and cognitive impairment due to pharmacological intervention Caused disease (e.g., chemotherapy-induced cognitive impairment, also known as Kemoburein) is a method of treating,. |